4//SEC Filing
Renger John 4
Accession 0000950170-24-012962
CIK 0001805387other
Filed
Feb 7, 7:00 PM ET
Accepted
Feb 8, 7:19 PM ET
Size
9.5 KB
Accession
0000950170-24-012962
Insider Transaction Report
Form 4
Renger John
Chief Scientific Officer
Transactions
- Sale
Common Stock
2024-02-07$41.54/sh−2,161$89,777→ 6,370 total - Exercise/Conversion
Restricted Stock Units
2024-02-06−5,020→ 15,061 total→ Common Stock (5,020 underlying) - Exercise/Conversion
Common Stock
2024-02-06+5,020→ 8,531 total
Footnotes (5)
- [F1]Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock.
- [F2]Includes 807 shares previously acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2023.
- [F3]The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.42 to $41.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date.
Documents
Issuer
Cerevel Therapeutics Holdings, Inc.
CIK 0001805387
Entity typeother
Related Parties
1- filerCIK 0001830363
Filing Metadata
- Form type
- 4
- Filed
- Feb 7, 7:00 PM ET
- Accepted
- Feb 8, 7:19 PM ET
- Size
- 9.5 KB